After the virus reached American shores, was the FDA quick enough to allow companies and labs to develop their own tests without restrictive oversight? The question sparked a sweeping new bill in congress, the VALID Act that could overhaul FDA oversight of diagnostics altogether—something that has been clamored for for a generation. Turna Ray has been covering the FDA and diagnostics for GenomeWeb since 2006. She has recently written a piece on the new VALID Act that includes responses from various members of the community.
Share this post

FDA in the Time of Coronavirus: Understanding the New VALID Act with Turna Ray, GenomeWeb
www.mendelspod.com
Mendelspod Podcast
Offering a front row seat to the Century of Biology, veteran podcast host Theral Timpson interviews the who's who in genomics and genomic medicine.
Listen on
Substack App
Apple Podcasts
RSS Feed
FDA in the Time of Coronavirus: Understanding the New VALID Act with Turna Ray, GenomeWeb